Data Collection on Rare Coagulation Disorders: Focus on Patients with Coagulation Factor X Deficiency
Haemophilia · 29.10.2026
DOI: 10.1111/hae.70447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, online erschienen am 29.10.2026. Verfasst von Marzia Menegatti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, …. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Kedrion SpA.
Abstract (Originalsprache)
Background
Inherited coagulation factor X (FX) deficiency is an ultra‐rare coagulation disorder (estimated prevalence ∼1:1,000,000), characterized by reduced FX activity (FX:C) and bleeding manifestations, ranging from mild to life‐threatening hemorrhage. Due to its rarity, management is currently guided by case reports and expert opinion rather than evidence‐based guidelines.
Objectives
The Prospective Rare Bleeding Disorders Database on Coagulation Factor X Deficiency (PRO‐RBDD‐FX) aims to quantify bleeding rates, identify FX:C thresholds protective against major spontaneous bleeding and evaluate treatment efficacy and safety. A secondary objective is to assess the health‐related quality of life (HrQoL).
Methods
PRO‐RBDD‐FX is an observational study utilizing a web‐based platform for the collection of retrospective and prospective longitudinal data. The registry enrolls affected probands and their first‐degree relatives. Standardized demographic, clinical, laboratory, genetic, and treatment‐related data are collected through dedicated modules covering bleeding manifestations, surgery, prophylaxis, thrombosis, laboratory phenotype assessment, genetics, and HrQoL. Bleeding severity is quantified using the ISTH‐BAT and the EN‐RBD‐BSS, while HrQoL is assessed through EuroQoL questionnaires.
Results
The PRO‐RBDD‐FX project resulted in the development of a web‐based registry dedicated to FX deficiency. The platform integrates clinical, laboratory, genetic, therapeutic, and patient‐reported outcome data within a unified longitudinal follow‐up.
Conclusions
The disease‐specific modules developed herein support future natural history and genotype–phenotype studies. The PRO‐RBDD‐FX registry represents a tool for advancing research in ultra‐rare diseases, bridging the gap between laboratory findings and clinical reality promoting standardized personalized care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy.
- Taomix Srl, Milan, Italy.
- Department of Oncology and HematoOncology, Università Degli Studi di Milano, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.
Förderung
- Kedrion SpA
Zitieren
APA
Menegatti, M., Mohsenian, S., Lanzi, P., Cutica, I., Siboni, S. M., & Peyvandi, F. (2026). Data Collection on Rare Coagulation Disorders: Focus on Patients with Coagulation Factor X Deficiency. Haemophilia. https://doi.org/10.1111/hae.70447
Vancouver
Menegatti M, Mohsenian S, Lanzi P, Cutica I, Siboni SM, Peyvandi F. Data Collection on Rare Coagulation Disorders: Focus on Patients with Coagulation Factor X Deficiency. Haemophilia. 2026. doi:10.1111/hae.70447
BibTeX
@article{Menegatti2026,
author = {Menegatti, Marzia and Mohsenian, Samin and Lanzi, Paolo and Cutica, Ilaria and Siboni, Simona Maria and Peyvandi, Flora},
title = {Data Collection on Rare Coagulation Disorders: Focus on Patients with Coagulation Factor X Deficiency},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70447}
}
EUVIMED